Berkeley Limketkai, MD PhD

Solomon Scholars Research Day 2025 was a success! Residents across our seven UCLA-affiliated internal medicine programs gathered to share innovative research and case studies. Watch the recap video to learn from some of the presenters about their projects: uclahs.fyi/4moVfyu

ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease - PubMed Malnutrition, defined as deficiency, excess, or imbalance of nutrients, is a common complication in patients with liver disease, especially those with cirrhosis. Malnutrition may present as an isolate...

🔥off the press: @amcollegegastro.bsky.social guideline on nutrition/malnutrition for liver disease.

pubmed.gov/40314389

Mark Baniqued shares our findings of food insecurity among individuals with #IBD in US (13% with #IBD vs. 8% without IBD).

Diet therapies don't work for patients who cannot even afford them.

#DDW2025 @ddwmeeting.bsky.social

🚨 Our new commentary in aga-gastro.bsky.social highlights best practices for diagnosing, treating, and monitoring Crohn’s perianal fistula.
📖 Read more: gastro.org/news/best-pr....

#GIsky

Dr. Dana Lukin provides takeaways from this study published in @aga-gastro.bsky.social that found wearable devices like the Apple Watch and Fitbit may help predict #IBD flares. www.mdedge.com/gihepnews/ar...

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial Appendicectomy is superior to standard medical therapy alone in maintaining remission in patients with ulcerative colitis.

New research - Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky

Such an honor to be invited to be a #DDW2025 dietitian presenter!

I am co-presenting w/expert GI MDs Lena B. Palmer, MD, Matthew R. Kappus, MD, & Inuk Zandvakili, MD at @ddwmeeting.bsky.social

🗣️ A User's Guide to the Sarcopenic Patient in GI Clinic
🗓️ Tuesday, 5/6/25
🕰️ 10-11:30 AM PST

🚨 NIH funding changes threaten #GIResearch labs and the future of GI patient care! 🚨 AGA President Maria T. Abreu calls for action. Share your story about how these changes impact your work. Let's protect the future of digestive disease treatment! https://buff.ly/40WPmyC

For #IBD folks dealing with pain, this could be a big deal.
www.nature.com/articles/d41...
Lots of data on surgical pain.
Affects sodium channels, not opioid receptors.
Availability and price/coverage TBD.
@ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social

Read here. Now published! A review on “Patient-Centered Plant-based Approach to Diets for Gastrointestinal Disorders” in Practical Gastroenterology by Anh Trinh Doan, DO, Anna Simon, DO, Ian Fladie, DO, Alexis Bejcek, MD, & Vani Paleti, MD.

practicalgastro.com/wp-content/u...

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

FDA approves mirikizumab for moderately to severely active Crohn’s disease

www.prnewswire.com/news-release...

#GastroSky #MedSky #IDSky

Cover of The Lancet's Jan 18th, 2025 issue. Quote reads: "Disinformation has become a deliberate instrument to attack and discredit scientists and health professionals for political gains. The effects are destructive and damaging to public health."

The spread of health misinformation and disinformation poses a serious threat to public health.

How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health?

Find out more in our latest Editorial: tinyurl.com/mtf95p25

🌟 Our new clinical practice update on endoscopic enteral access is out! Discover the best practices for tube selection, access points, and feeding methods for patients with inadequate oral intake. #GIsky #ClinicalPracticeUpdate

Say hello to @aga-gihn.bsky.social, AGA's official newspaper, on bsky and follow for articles on the latest in GI!

Too bad filgotinib was not superior for all wk 10 primary endpoints for #CD. This may have partly been due to mandatory steroid tapering not starting until wk 14 (unlike U-EXCEL/U-EXCEED upadacitinib trials that started at wk 4).

Filgotinib will now have a higher bar to climb for positioning.

🆕 AGA living guideline for moderate-to-severe #UlcerativeColitis. ⤵️

Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy.

gastro.org/clinical-gui...

Real-world data of JAK-inhs from Japan, comparing UPA, FIL and TOF

- UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies
- UPA: acne is quite common (23%), a relevant side-effect for some patients
- FIL = TOF

#IBDSky

onlinelibrary.wiley.com/doi/10.1111/...

🎨 In case anyone need…

The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!

Check it out 👇
bioart.niaid.nih.gov

Hopefully, we can also see Crohn’s & Colitis Foundation here in the not too distant future? @alanmoss.bsky.social

AGA has joined the party. Welcome!

Early bird rate for #CCCongress25 ends on Wednesday ⏰
🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰
👩‍🏫 #IBD A-Z
💪 Surgery prehabilitation
🚨Ultrasound training course with #IUSCAN #IBUS
@edelblumlab.bsky.social
#AGA
crohnscolitiscongress.org

Hot🔥 off the press! Living guidelines for pharmacological treatment of #UC

@jhaydek.bsky.social presents an excellent skytorial

The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.

ow.ly/t2Ru50UahEi

Towards better understanding how we should position advanced tx in UC:

Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...

And so begins my journey in this new community. Hopefully, Blue Sky lives up to its name. 😊